

# 2019 Future of Insomnia R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/21739409DEFEN.html>

Date: February 2019

Pages: 90

Price: US\$ 2,199.00 (Single User License)

ID: 21739409DEFEN

## Abstracts

The global demand for Insomnia treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Insomnia pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Insomnia pipeline companies from advancing their products into Phase 3 or Phase 4.

### Insomnia Report Description-

The 2019 pipeline study on Insomnia pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Insomnia pipeline compounds.

The Insomnia pipeline guide presents information on all active drugs currently being developed for Insomnia. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Insomnia pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Insomnia drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Insomnia product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Insomnia pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Insomnia pipeline report includes-

An overview of Insomnia disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of Insomnia pipeline

Company wise list of Insomnia pipeline

Mechanism of Action wise Insomnia pipeline

For each pipeline candidate, the following details are provided

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials/Results

Company Overview and Recent Developments

## **REASONS TO BUY**

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Insomnia pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Insomnia pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into companies participating in Insomnia pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

## Contents

### 1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

### 2. GLOBAL INSOMNIA PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Research Methodology

### 3. EXECUTIVE SUMMARY

- 3.1 Insomnia Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development
  - 3.2.1 Pre-clinical
  - 3.2.2 Discovery
  - 3.2.3 Phase
  - 3.2.4Phase
- 3.3 Pipeline Drugs in Advanced Stage of Development
  - 3.3.1 Phase
  - 3.3.2 Pre-registration
- 3.4 Companies involved in Insomnia pipeline, H1- 2019
- 3.5 Mechanism of Action wise Insomnia Pipeline Candidates

### 4 ALEXZA PHARMACEUTICALS INC INSOMNIA PIPELINE DETAILS

- 4.1 Alexza Pharmaceuticals Inc Business Profile
- 4.2 Alexza Pharmaceuticals Inc Insomnia Drug Details
- 4.3 Drug Snapshot
  - 4.3.1 Originator
  - 4.3.2 Collaborator/Co-Developer
  - 4.3.3 Route of Administration
  - 4.3.4 Orphan Drug/Fast Track/Special Designation
  - 4.3.5 Geography
  - 4.3.6 Type of Molecular Entity
  - 4.3.7 Current Status

- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

## **5 AMHERST PHARMACEUTICALS LLC INSOMNIA PIPELINE DETAILS**

- 5.1 Amherst Pharmaceuticals LLC Business Profile
- 5.2 Amherst Pharmaceuticals LLC Insomnia Drug Details
- 5.3 Drug Snapshot
  - 5.3.1 Originator
  - 5.3.2 Collaborator/Co-Developer
  - 5.3.3 Route of Administration
  - 5.3.4 Orphan Drug/Fast Track/Special Designation
  - 5.3.5 Geography
  - 5.3.6 Type of Molecular Entity
  - 5.3.7 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

## **6 BLAKE INSOMNIA THERAPEUTICS INC INSOMNIA PIPELINE DETAILS**

- 6.1 Blake Insomnia Therapeutics Inc Business Profile
- 6.2 Blake Insomnia Therapeutics Inc Insomnia Drug Details
- 6.3 Drug Snapshot
  - 6.3.1 Originator
  - 6.3.2 Collaborator/Co-Developer
  - 6.3.3 Route of Administration
  - 6.3.4 Orphan Drug/Fast Track/Special Designation
  - 6.3.5 Geography
  - 6.3.6 Type of Molecular Entity
  - 6.3.7 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

## **7 CENNERV PHARMACEUTICALS LTD INSOMNIA PIPELINE DETAILS**

- 7.1 Cennerv Pharmaceuticals Ltd Business Profile
- 7.2 Cennerv Pharmaceuticals Ltd Insomnia Drug Details
- 7.3 Drug Snapshot
  - 7.3.1 Originator
  - 7.3.2 Collaborator/Co-Developer
  - 7.3.3 Route of Administration
  - 7.3.4 Orphan Drug/Fast Track/Special Designation
  - 7.3.5 Geography
  - 7.3.6 Type of Molecular Entity
  - 7.3.7 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

## **8 COSMAS THERAPEUTICS DEVELOPMENT INC INSOMNIA PIPELINE DETAILS**

- 8.1 Cosmas Therapeutics Development Inc Business Profile
- 8.2 Cosmas Therapeutics Development Inc Insomnia Drug Details
- 8.3 Drug Snapshot
  - 8.3.1 Originator
  - 8.3.2 Collaborator/Co-Developer
  - 8.3.3 Route of Administration
  - 8.3.4 Orphan Drug/Fast Track/Special Designation
  - 8.3.5 Geography
  - 8.3.6 Type of Molecular Entity
  - 8.3.7 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

## **9 DRUGGABILITY TECHNOLOGIES HOLDINGS LTD INSOMNIA PIPELINE DETAILS**

- 9.1 Druggability Technologies Holdings Ltd Business Profile
- 9.2 Druggability Technologies Holdings Ltd Insomnia Drug Details

## 9.3 Drug Snapshot

- 9.3.1 Originator
- 9.3.2 Collaborator/Co-Developer
- 9.3.3 Route of Administration
- 9.3.4 Orphan Drug/Fast Track/Special Designation
- 9.3.5 Geography
- 9.3.6 Type of Molecular Entity
- 9.3.7 Current Status

## 9.4 Drug Overview

## 9.5 Drug Mechanism of Action

## 9.6 Clinical/Pre-clinical Trial Details

## 9.7 Latest Drug Developments

# 10 EISAI CO LTD INSOMNIA PIPELINE DETAILS

## 10.1 Eisai Co Ltd Business Profile

## 10.2 Eisai Co Ltd Insomnia Drug Details

## 10.3 Drug Snapshot

- 10.3.1 Originator
- 10.3.2 Collaborator/Co-Developer
- 10.3.3 Route of Administration
- 10.3.4 Orphan Drug/Fast Track/Special Designation
- 10.3.5 Geography
- 10.3.6 Type of Molecular Entity
- 10.3.7 Current Status

## 10.4 Drug Overview

## 10.5 Drug Mechanism of Action

## 10.6 Clinical/Pre-clinical Trial Details

## 10.7 Latest Drug Developments

# 11 EVOTEC AG INSOMNIA PIPELINE DETAILS

## 11.1 Evotec AG Business Profile

## 11.2 Evotec AG Insomnia Drug Details

## 11.3 Drug Snapshot

- 11.3.1 Originator
- 11.3.2 Collaborator/Co-Developer
- 11.3.3 Route of Administration
- 11.3.4 Orphan Drug/Fast Track/Special Designation

- 11.3.5 Geography
- 11.3.6 Type of Molecular Entity
- 11.3.7 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details
- 11.7 Latest Drug Developments

## **12 GRUPO FERRER INTERNACIONAL SA INSOMNIA PIPELINE DETAILS**

- 12.1 Grupo Ferrer Internacional SA Business Profile
- 12.2 Grupo Ferrer Internacional SA Insomnia Drug Details
- 12.3 Drug Snapshot
  - 12.3.1 Originator
  - 12.3.2 Collaborator/Co-Developer
  - 12.3.3 Route of Administration
  - 12.3.4 Orphan Drug/Fast Track/Special Designation
  - 12.3.5 Geography
  - 12.3.6 Type of Molecular Entity
  - 12.3.7 Current Status
- 12.4 Drug Overview
- 12.5 Drug Mechanism of Action
- 12.6 Clinical/Pre-clinical Trial Details
- 12.7 Latest Drug Developments

## **13 HEPTARES THERAPEUTICS LTD INSOMNIA PIPELINE DETAILS**

- 13.1 Heptares Therapeutics Ltd Business Profile
- 13.2 Heptares Therapeutics Ltd Insomnia Drug Details
- 13.3 Drug Snapshot
  - 13.3.1 Originator
  - 13.3.2 Collaborator/Co-Developer
  - 13.3.3 Route of Administration
  - 13.3.4 Orphan Drug/Fast Track/Special Designation
  - 13.3.5 Geography
  - 13.3.6 Type of Molecular Entity
  - 13.3.7 Current Status
- 13.4 Drug Overview
- 13.5 Drug Mechanism of Action



- 13.6 Clinical/Pre-clinical Trial Details
- 13.7 Latest Drug Developments

## **14 IDORSIA PHARMACEUTICAL LTD INSOMNIA PIPELINE DETAILS**

- 14.1 Idorsia Pharmaceutical Ltd Business Profile
- 14.2 Idorsia Pharmaceutical Ltd Insomnia Drug Details
- 14.3 Drug Snapshot
  - 14.3.1 Originator
  - 14.3.2 Collaborator/Co-Developer
  - 14.3.3 Route of Administration
  - 14.3.4 Orphan Drug/Fast Track/Special Designation
  - 14.3.5 Geography
  - 14.3.6 Type of Molecular Entity
  - 14.3.7 Current Status
- 14.4 Drug Overview
- 14.5 Drug Mechanism of Action
- 14.6 Clinical/Pre-clinical Trial Details
- 14.7 Latest Drug Developments

## **15 INTRA-CELLULAR THERAPIES INC INSOMNIA PIPELINE DETAILS**

- 15.1 Intra-Cellular Therapies Inc Business Profile
- 15.2 Intra-Cellular Therapies Inc Insomnia Drug Details
- 15.3 Drug Snapshot
  - 15.3.1 Originator
  - 15.3.2 Collaborator/Co-Developer
  - 15.3.3 Route of Administration
  - 15.3.4 Orphan Drug/Fast Track/Special Designation
  - 15.3.5 Geography
  - 15.3.6 Type of Molecular Entity
  - 15.3.7 Current Status
- 15.4 Drug Overview
- 15.5 Drug Mechanism of Action
- 15.6 Clinical/Pre-clinical Trial Details
- 15.7 Latest Drug Developments

## **16 JANSSEN PHARMACEUTICALS INSOMNIA PIPELINE DETAILS**

- 16.1 Janssen Pharmaceuticals Business Profile
- 16.2 Janssen Pharmaceuticals Insomnia Drug Details
- 16.3 Drug Snapshot
  - 16.3.1 Originator
  - 16.3.2 Collaborator/Co-Developer
  - 16.3.3 Route of Administration
  - 16.3.4 Orphan Drug/Fast Track/Special Designation
  - 16.3.5 Geography
  - 16.3.6 Type of Molecular Entity
  - 16.3.7 Current Status
- 16.4 Drug Overview
- 16.5 Drug Mechanism of Action
- 16.6 Clinical/Pre-clinical Trial Details
- 16.7 Latest Drug Developments

## **17 LEADING BIOSCIENCES INC INSOMNIA PIPELINE DETAILS**

- 17.1 Leading BioSciences Inc Business Profile
- 17.2 Leading BioSciences Inc Insomnia Drug Details
- 17.3 Drug Snapshot
  - 17.3.1 Originator
  - 17.3.2 Collaborator/Co-Developer
  - 17.3.3 Route of Administration
  - 17.3.4 Orphan Drug/Fast Track/Special Designation
  - 17.3.5 Geography
  - 17.3.6 Type of Molecular Entity
  - 17.3.7 Current Status
- 17.4 Drug Overview
- 17.5 Drug Mechanism of Action
- 17.6 Clinical/Pre-clinical Trial Details
- 17.7 Latest Drug Developments

## **18 LINNET BIOPHARMACEUTICALS INC INSOMNIA PIPELINE DETAILS**

- 18.1 Linnet BioPharmaceuticals Inc Business Profile
- 18.2 Linnet BioPharmaceuticals Inc Insomnia Drug Details
- 18.3 Drug Snapshot
  - 18.3.1 Originator
  - 18.3.2 Collaborator/Co-Developer

- 18.3.3 Route of Administration
- 18.3.4 Orphan Drug/Fast Track/Special Designation
- 18.3.5 Geography
- 18.3.6 Type of Molecular Entity
- 18.3.7 Current Status
- 18.4 Drug Overview
- 18.5 Drug Mechanism of Action
- 18.6 Clinical/Pre-clinical Trial Details
- 18.7 Latest Drug Developments

## **19 MERCK & CO INC INSOMNIA PIPELINE DETAILS**

- 19.1 Merck & Co Inc Business Profile
- 19.2 Merck & Co Inc Insomnia Drug Details
- 19.3 Drug Snapshot
  - 19.3.1 Originator
  - 19.3.2 Collaborator/Co-Developer
  - 19.3.3 Route of Administration
  - 19.3.4 Orphan Drug/Fast Track/Special Designation
  - 19.3.5 Geography
  - 19.3.6 Type of Molecular Entity
  - 19.3.7 Current Status
- 19.4 Drug Overview
- 19.5 Drug Mechanism of Action
- 19.6 Clinical/Pre-clinical Trial Details
- 19.7 Latest Drug Developments

## **20 NB HEALTH LABORATORY CO LTD INSOMNIA PIPELINE DETAILS**

- 20.1 NB Health Laboratory Co Ltd Business Profile
- 20.2 NB Health Laboratory Co Ltd Insomnia Drug Details
- 20.3 Drug Snapshot
  - 20.3.1 Originator
  - 20.3.2 Collaborator/Co-Developer
  - 20.3.3 Route of Administration
  - 20.3.4 Orphan Drug/Fast Track/Special Designation
  - 20.3.5 Geography
  - 20.3.6 Type of Molecular Entity
  - 20.3.7 Current Status

- 20.4 Drug Overview
- 20.5 Drug Mechanism of Action
- 20.6 Clinical/Pre-clinical Trial Details
- 20.7 Latest Drug Developments

## **21 NEURIM PHARMACEUTICALS LTD INSOMNIA PIPELINE DETAILS**

- 21.1 Neurim Pharmaceuticals Ltd Business Profile
- 21.2 Neurim Pharmaceuticals Ltd Insomnia Drug Details
- 21.3 Drug Snapshot
  - 21.3.1 Originator
  - 21.3.2 Collaborator/Co-Developer
  - 21.3.3 Route of Administration
  - 21.3.4 Orphan Drug/Fast Track/Special Designation
  - 21.3.5 Geography
  - 21.3.6 Type of Molecular Entity
  - 21.3.7 Current Status
- 21.4 Drug Overview
- 21.5 Drug Mechanism of Action
- 21.6 Clinical/Pre-clinical Trial Details
- 21.7 Latest Drug Developments

## **22 NEUROFIX THERAPEUTICS LLC INSOMNIA PIPELINE DETAILS**

- 22.1 NeuroFix Therapeutics LLC Business Profile
- 22.2 NeuroFix Therapeutics LLC Insomnia Drug Details
- 22.3 Drug Snapshot
  - 22.3.1 Originator
  - 22.3.2 Collaborator/Co-Developer
  - 22.3.3 Route of Administration
  - 22.3.4 Orphan Drug/Fast Track/Special Designation
  - 22.3.5 Geography
  - 22.3.6 Type of Molecular Entity
  - 22.3.7 Current Status
- 22.4 Drug Overview
- 22.5 Drug Mechanism of Action
- 22.6 Clinical/Pre-clinical Trial Details
- 22.7 Latest Drug Developments

## **23 OVERSEAS PHARMACEUTICALS LTD INSOMNIA PIPELINE DETAILS**

- 23.1 Overseas Pharmaceuticals Ltd Business Profile
- 23.2 Overseas Pharmaceuticals Ltd Insomnia Drug Details
- 23.3 Drug Snapshot
  - 23.3.1 Originator
  - 23.3.2 Collaborator/Co-Developer
  - 23.3.3 Route of Administration
  - 23.3.4 Orphan Drug/Fast Track/Special Designation
  - 23.3.5 Geography
  - 23.3.6 Type of Molecular Entity
  - 23.3.7 Current Status
- 23.4 Drug Overview
- 23.5 Drug Mechanism of Action
- 23.6 Clinical/Pre-clinical Trial Details
- 23.7 Latest Drug Developments

## **24 PURDUE PHARMA LP INSOMNIA PIPELINE DETAILS**

- 24.1 Purdue Pharma LP Business Profile
- 24.2 Purdue Pharma LP Insomnia Drug Details
- 24.3 Drug Snapshot
  - 24.3.1 Originator
  - 24.3.2 Collaborator/Co-Developer
  - 24.3.3 Route of Administration
  - 24.3.4 Orphan Drug/Fast Track/Special Designation
  - 24.3.5 Geography
  - 24.3.6 Type of Molecular Entity
  - 24.3.7 Current Status
- 24.4 Drug Overview
- 24.5 Drug Mechanism of Action
- 24.6 Clinical/Pre-clinical Trial Details
- 24.7 Latest Drug Developments

## **25 REVIVA PHARMACEUTICALS INC INSOMNIA PIPELINE DETAILS**

- 25.1 Reviva Pharmaceuticals Inc Business Profile
- 25.2 Reviva Pharmaceuticals Inc Insomnia Drug Details
- 25.3 Drug Snapshot

- 25.3.1 Originator
- 25.3.2 Collaborator/Co-Developer
- 25.3.3 Route of Administration
- 25.3.4 Orphan Drug/Fast Track/Special Designation
- 25.3.5 Geography
- 25.3.6 Type of Molecular Entity
- 25.3.7 Current Status
- 25.4 Drug Overview
- 25.5 Drug Mechanism of Action
- 25.6 Clinical/Pre-clinical Trial Details
- 25.7 Latest Drug Developments

## **26 SAGE THERAPEUTICS INC INSOMNIA PIPELINE DETAILS**

- 26.1 Sage Therapeutics Inc Business Profile
- 26.2 Sage Therapeutics Inc Insomnia Drug Details
- 26.3 Drug Snapshot
  - 26.3.1 Originator
  - 26.3.2 Collaborator/Co-Developer
  - 26.3.3 Route of Administration
  - 26.3.4 Orphan Drug/Fast Track/Special Designation
  - 26.3.5 Geography
  - 26.3.6 Type of Molecular Entity
  - 26.3.7 Current Status
- 26.4 Drug Overview
- 26.5 Drug Mechanism of Action
- 26.6 Clinical/Pre-clinical Trial Details
- 26.7 Latest Drug Developments

## **27 SHIONOGI & CO LTD INSOMNIA PIPELINE DETAILS**

- 27.1 Shionogi & Co Ltd Business Profile
- 27.2 Shionogi & Co Ltd Insomnia Drug Details
- 27.3 Drug Snapshot
  - 27.3.1 Originator
  - 27.3.2 Collaborator/Co-Developer
  - 27.3.3 Route of Administration
  - 27.3.4 Orphan Drug/Fast Track/Special Designation
  - 27.3.5 Geography

- 27.3.6 Type of Molecular Entity
- 27.3.7 Current Status
- 27.4 Drug Overview
- 27.5 Drug Mechanism of Action
- 27.6 Clinical/Pre-clinical Trial Details
- 27.7 Latest Drug Developments

## **28 TAISHO PHARMACEUTICAL HOLDINGS CO LTD INSOMNIA PIPELINE DETAILS**

- 28.1 Taisho Pharmaceutical Holdings Co Ltd Business Profile
- 28.2 Taisho Pharmaceutical Holdings Co Ltd Insomnia Drug Details
- 28.3 Drug Snapshot
  - 28.3.1 Originator
  - 28.3.2 Collaborator/Co-Developer
  - 28.3.3 Route of Administration
  - 28.3.4 Orphan Drug/Fast Track/Special Designation
  - 28.3.5 Geography
  - 28.3.6 Type of Molecular Entity
  - 28.3.7 Current Status
- 28.4 Drug Overview
- 28.5 Drug Mechanism of Action
- 28.6 Clinical/Pre-clinical Trial Details
- 28.7 Latest Drug Developments

## **29 ZELDA THERAPEUTICS PTY LTD INSOMNIA PIPELINE DETAILS**

- 29.1 Zelda Therapeutics Pty Ltd Business Profile
- 29.2 Zelda Therapeutics Pty Ltd Insomnia Drug Details
- 29.3 Drug Snapshot
  - 29.3.1 Originator
  - 29.3.2 Collaborator/Co-Developer
  - 29.3.3 Route of Administration
  - 29.3.4 Orphan Drug/Fast Track/Special Designation
  - 29.3.5 Geography
  - 29.3.6 Type of Molecular Entity
  - 29.3.7 Current Status
- 29.4 Drug Overview
- 29.5 Drug Mechanism of Action

29.6 Clinical/Pre-clinical Trial Details  
29.7 Latest Drug Developments

### **30. LATEST INSOMNIA DRUG PIPELINE DEVELOPMENTS, 2019**

### **31. APPENDIX**

31.1 About Us  
31.2 Sources and Methodology  
31.3 Contact Information



## I would like to order

Product name: 2019 Future of Insomnia R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/21739409DEFEN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/21739409DEFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

